Mabcampath (alemtuzumab): withdrawal of the marketing authorisation

The marketing authorisation (MA) for Mabcampath has been withdrawn at the European level, on the initiative of the MA holder, Genzyme Europe BV, for commercial reasons. Mabcampath is a monoclonal antibody (alemtuzumab) used in some chronic lymphocytic leukaemia. Appropriate access to this medicine will be implemented in each Member State to ensure that patients who are currently benefiting from the treatment can continue.

 

Press release

 

Contact : vig@afmps.be

 

Last updated on
18/09/2012